Biocon Ltd.

NSE: BIOCON | BSE: 532523 | ISIN: INE376G01013 | Industry: Biotechnology
| Mid-range Performer
372.4000 -1.15 (-0.31%)
NSE Jul 10, 2025 15:52 PM
Volume: 1.9M
 

logo
Biocon Ltd.
03 Dec 2017
372.40
-0.31%
Motilal Oswal
Mylan/ Biocon announced on Friday that US FDA approved Mylan's Ogivr (trastuzumab-dkst), a biosimilar to Herceptin (trastuzumab), co-developed with Biocon. Ogivri is the first FDA-approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the US. Notably, Mylan is the only player which has settled for a launch date with innovator Roche. Mylan anticipates to be the first player to launch biosimilar version of Herceptin. Patent for Herceptin is expiring in mid-2019. Since Biocon has not filed this product through interchangeable route, it will not receive exclusivity...
Biocon Ltd. has an average target of 389.25 from 4 brokers.
More from Biocon Ltd.
Recommended